Michael Okunewitch
Stock Analyst at Maxim Group
(1.73)
# 3,259
Out of 4,915 analysts
27
Total ratings
29.17%
Success rate
-4.03%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $2.88 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $4.30 | +713.95% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $2.16 | - | 2 | May 23, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.72 | +154.24% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.08 | +548.15% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.84 | +660.87% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.03 | +191.26% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.07 | +273.83% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.63 | +1,790.66% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.58 | +279.75% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.92 | +1,211.48% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.32 | +1,718.18% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.68 | +571.64% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.52 | +80,257.14% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $19.33 | +29.33% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.48 | +305.41% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.47 | +620.46% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.39 | +7,094.24% | 1 | Nov 30, 2021 |
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.88
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $4.30
Upside: +713.95%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.16
Upside: -
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.72
Upside: +154.24%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.08
Upside: +548.15%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.84
Upside: +660.87%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.03
Upside: +191.26%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.07
Upside: +273.83%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.63
Upside: +1,790.66%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.58
Upside: +279.75%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.92
Upside: +1,211.48%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.32
Upside: +1,718.18%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.68
Upside: +571.64%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.52
Upside: +80,257.14%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $19.33
Upside: +29.33%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.48
Upside: +305.41%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.47
Upside: +620.46%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.39
Upside: +7,094.24%